Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results